Administrative, Leadership Development and Advocacy Core

核心A：摘要 前列腺癌中的孢子汇集了一个高度积极的多学科研究团队，来自 西北大学和芝加哥大学，北岸大学贡献 HealthSystem(UC附属公司)。该团队包括实验室科学家、泌尿科医生、内科肿瘤学家、 病理学家、生物统计学家和生物信息学家，他们都致力于进行最先进的 旨在开发和测试干预措施以改善确诊患者预后的转化性研究 前列腺癌。 行政、领导力发展和宣传核心有以下具体目标： 具体目标1：在孢子内提供整合，并与罗伯特·H·卢里综合癌症 中心和芝加哥大学综合癌症中心 具体目标2：通过以下方式对研究项目和核心提供强有力的监督以及财务监督 规划和评价活动 具体目标3：监督发展研究(DRP)和职业提升(CEP)计划 鼓励研究人员进行前列腺癌翻译研究的孢子 具体目标4：领导一个倡导团体和社区的多样性教育倡议 具体目标5：培养前列腺癌研究的下一代领导者 具体目标6：促进与美国国立卫生研究院和其他国家资助的方案的合作和融合 作为U54 CA203000(芝加哥促进和推进癌症健康公平合作组织)，该部 国防和前列腺癌基金会。

CORE A: ABSTRACT The SPORE in Prostate Cancer brings together a highly motivated multidisciplinary team of investigators from Northwestern University and the University of Chicago, with contributions from NorthShore University HealthSystem (UC affiliate). The team includes laboratory scientists, urologists, medical oncologists, pathologists, biostatisticians and bioinformaticians, all of whom are dedicated to conducting state-of-the-art translational research to develop and test interventions that improve the outcome of patients diagnosed with prostate cancer. The Administrative, Leadership Development and Advocacy Core has the following Specific Aims: Specific Aim 1: To provide integration within the SPORE, and with the Robert H. Lurie Comprehensive Cancer Center and the University of Chicago Comprehensive Cancer Center Specific Aim 2: To provide strong oversight of research projects and cores as well as financial oversight through planning and evaluation activities Specific Aim 3: To oversee the Developmental Research (DRP) and Career Enhancement (CEP) Programs of the SPORE to encourage investigators to conduct translational prostate cancer research Specific Aim 4: To lead an advocacy group and diversity education initiatives in the community Specific Aim 5: To train the next generation of leaders in prostate cancer research Specific Aim 6: To facilitate collaborations and integration with NIH and other nationally funded programs such as the U54 CA203000 (The Chicago Collaborative to Promote and Advance Cancer Health Equity), Department of Defense and Prostate Cancer Foundation.